Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK

Nature Communications

Volumn 7, Issue , 2016, Pages

  Wang, Jieqiong ^a,b   Hu, Kewen ^a   Guo, Jiawei ^a   Cheng, Feixiong ^c,d   Lv, Jing ^a   Jiang, Wenhao ^a   Lu, Weiqiang ^a   Liu, Jinsong ^e   Pang, Xiufeng ^a   Liu, Mingyao ^a,f  

^a EAST CHINA NORMAL UNIVERSITY   (China)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^c SICHUAN UNIVERSITY   (China)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; FASUDIL; K RAS PROTEIN; POLO LIKE KINASE 1; RHO KINASE; ANTINEOPLASTIC AGENT; CELL CYCLE PROTEIN; ENZYME INHIBITOR; KRAS PROTEIN, HUMAN; ONCOPROTEIN; POLO-LIKE KINASE 1; PROTEIN P21; PROTEIN P53; PROTEIN SERINE THREONINE KINASE;

CANCER; ENZYME ACTIVITY; GENE EXPRESSION; GROWTH RATE; INHIBITION; RODENT; SURVIVAL; TUMOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME INHIBITION; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; C57BL MOUSE; CELL CYCLE G2 PHASE; CELL DIVISION; DRUG EFFECT; ENZYMOLOGY; FEMALE; GENETICS; LUNG TUMOR; MALE; METABOLISM; MUTATION; PATHOPHYSIOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE PROTEINS; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; ENZYME INHIBITORS; FEMALE; G2 PHASE; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MUTATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS P21(RAS); RHO-ASSOCIATED KINASES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84970016479     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms11363     Document Type: Article

References (55)

1. Thompson, H. US National Cancer Institute's new Ras project targets an old foe. Nat. Med. 19, 949-950 (2013).
2. Karnoub, A. E. & Weinberg, R. A. Ras oncogenes: split personalities. Nat. Rev. Mol. Cell Biol. 9, 517-531 (2008).
3. Baines, A. T., Xu, D. & Der, C. J. Inhibition of Ras for cancer treatment: the search continues. Future Med. Chem. 3, 1787-1808 (2011).
4. Siegel, R., Ma, J., Zou, Z. & Jemal, A. Cancer statistics, 2014. CA Cancer J. Clin. 64, 9-29 (2014).
5. Luo, J., Solimini, N. L. & Elledge, S. J. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136, 823-837 (2009).
6. Singh, A. et al. A gene expression signature associated with 'K-Ras addiction' reveals regulators of EMT and tumor cell survival. Cancer Cell 15, 489-500 (2009).
7. Pylayeva-Gupta, Y., Grabocka, E. & Bar-Sagi, D. RAS oncogenes: weaving a tumorigenic web. Nat. Rev. Cancer 11, 761-774 (2011).
8. Russo, M., Di Nicolantonio, F. & Bardelli, A. Climbing RAS, the everest of oncogenes. Cancer Discov. 4, 19-21 (2014).
9. Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A. & Shokat, K. M. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503, 548-551 (2013).
10. Wang, Y., Kaiser, C. E., Frett, B. & Li, H. Y. Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators. J. Med. Chem. 56, 5219-5230 (2013).
11. Adjei, A. A. et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J. Clin. Oncol. 26, 2139-2146 (2008).
12. Metro, G. et al. Selumetinib: a promising pharmacologic approach for KRASmutant advanced non-small-cell lung cancer. Future Oncol. 9, 167-177 (2013).
13. Turke, A. B. et al. MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. Cancer Res. 72, 3228-3237 (2012).
14. Barbie, D. A. et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462, 108-112 (2009).
15. Scholl, C. et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 137, 821-834 (2009).
16. Azoitei, N. et al. Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33. J. Exp. Med. 209, 697-711 (2012).
17. Luo, J. et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137, 835-848 (2009).
18. Weng, M. T. et al. Evolutionarily conserved protein ERH controls CENP-E mRNA splicing and is required for the survival of KRAS mutant cancer cells. Proc. Natl Acad. Sci. USA 109, E3659-E3667 (2012).
19. Puyol, M. et al. A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 18, 63-73 (2010).
20. Kumar, M. S. et al. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell 149, 642-655 (2012).
21. Steckel, M. et al. Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies. Cell Res. 22, 1227-1245 (2012).
22. Singh, A. et al. TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers. Cell 148, 639-650 (2012).
23. Corcoran, R. B. et al. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell 23, 121-128 (2013).
24. Yun, J. et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science 325, 1555-1559 (2009).
25. Holohan, C., Van Schaeybroeck, S., Longley, D. B. & Johnston, P. G. Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer 13, 714-726 (2013).
26. Xia, Y. et al. A combination therapy for KRAS-driven lung adenocarcinomas using lipophilic bisphosphonates and rapamycin. Sci. Transl. Med. 6, 263ra161 (2014).
27. Shimizu, T. et al. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin. Cancer Res. 18, 2316-2325 (2012).
28. Liu, J. et al. A genetically defined model for human ovarian cancer. Cancer Res. 64, 1655-1663 (2004).
29. Linardou, H. et al. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol. 9, 962-972 (2008).
30. Normanno, N. et al. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat. Rev. Clin. Oncol. 6, 519-527 (2009).
31. Levine, A. J. & Oren, M. The first 30 years of p53: growing ever more complex. Nat. Rev. Cancer 9, 749-758 (2009).
32. Fitzgerald, J. B., Schoeberl, B., Nielsen, U. B. & Sorger, P. K. Systems biology and combination therapy in the quest for clinical efficacy. Nat. Chem. Biol. 2, 458-466 (2006).
33. Karolchik, D. et al. The UCSC Genome Browser database: 2014 update. Nucleic Acids Res. 42, D764-D770 (2014).
34. Abbas, T. & Dutta, A. p21 in cancer: intricate networks and multiple activities. Nat. Rev. Cancer 9, 400-414 (2009).
35. Du Page, M., Dooley, A. L. & Jacks, T. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat. Protoc. 4, 1064-1072 (2009).
36. Jackson, E. L. et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 15, 3243-3248 (2001).
37. Stivala, L. A., Cazzalini, O. & Prosperi, E. The cyclin-dependent kinase inhibitor p21CDKN1A as a target of anti-cancer drugs. Curr. Cancer Drug Targets 12, 85-96 (2012).
38. Zimmermann, G. et al. Small molecule inhibition of the KRAS-PDEdelta interaction impairs oncogenic KRAS signalling. Nature 497, 638-642 (2013).
39. Engelman, J. A. et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med. 14, 1351-1356 (2008).
40. Acquaviva, J. et al. Targeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib. Mol. Cancer Ther. 11, 2633-2643 (2012).
41. Tolcher, A. W. et al. Antitumor activity in RAS-driven tumors by blocking AKT and MEK. Clin. Cancer Res. 21, 739-748 (2015).
42. Rovida, A. et al. Chemotherapy counteracts metastatic dissemination induced by antiangiogenic treatment in mice. Mol. Cancer Ther. 12, 2237-2247 (2013).
43. Shimoyama, T. et al. Effects of different combinations of gefitinib and irinotecan in lung cancer cell lines expressing wild or deletional EGFR. Lung Cancer 53, 13-21 (2006).
44. Waqar, S. N., Gopalan, P. K., Williams, K., Devarakonda, S. & Govindan, R. A phase I trial of sunitinib and rapamycin in patients with advanced non-small cell lung cancer. Chemotherapy 59, 8-13 (2013).
45. Kaelin, Jr W. G. The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer 5, 689-698 (2005).
46. Kroll, E. S., Hyland, K. M., Hieter, P. & Li, J. J. Establishing genetic interactions by a synthetic dosage lethality phenotype. Genetics 143, 95-102 (1996).
47. Sarthy, A. V. et al. Survivin depletion preferentially reduces the survival of activated K-Ras-transformed cells. Mol. Cancer Ther. 6, 269-276 (2007).
48. De Raedt, T. et al. Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. Cancer Cell 20, 400-413 (2011).
49. Chou, T. C. & Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22, 27-55 (1984).
50. Chou, T. C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58, 621-681 (2006).
51. Irizarry, R. A. et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4, 249-264 (2003).
52. Smyth, G. K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 3, Article3 (2004).
53. Yoav Benjamini, Y. H. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. B 57, 12 (1995).
54. Chaturvedi, M. M., Mukhopadhyay, A. & Aggarwal, B. B. Assay for redox-sensitive transcription factor. Methods Enzymol. 319, 585-602 (2000).
55. Wang, B. et al. The antiparasitic drug, potassium antimony tartrate, inhibits tumor angiogenesis and tumor growth in non-small cell lung cancer. J. Pharmacol. Exp. Ther. 352, 129-138 (2014).